Cerebrovascular Reactivity to Acetazolamide in Stable COPD Patients

Area of Science:

• Neurology
• Pulmonology
• Vascular Medicine

Background:

• COPD is linked to cerebral small vessel disease, white matter lesions, and cognitive decline.
• Systemic vascular dysfunction in COPD may extend to the brain, but the pathophysiology is unclear.
• Investigating cerebral hemodynamics in COPD is crucial for understanding these neurological complications.

Purpose of the Study:

• To evaluate acetazolamide-induced cerebral vasoreactivity (CVR) in COPD patients.
• To assess cerebrovascular reserve capacity (CVRC) in COPD patients.
• To determine if cerebral hemodynamics are impaired in COPD.

Main Methods:

• 17 COPD patients and 20 controls underwent transcranial Doppler.
• Acetazolamide was administered intravenously to induce vasodilation.
• CVR and CVRC were calculated based on middle cerebral artery blood flow velocity changes.

Main Results:

• Acetazolamide caused minor pH decrease and PaCO2 increase in COPD patients.
• Control subjects had higher absolute MBFV and lower pulsatility indices than COPD patients.
• No significant differences in CVR or CVRC were found between COPD patients and controls.

Conclusions:

• Cerebrovascular reactivity is not impaired in mild to moderate normocapnic COPD.
• Cerebral arteriolar function appears preserved in early stages of COPD.
• Future studies should investigate severe COPD stages to understand links to white matter lesions and cognitive decline.